Stockscreener 앱 받기
27.70
0.75%
-0.21
전일 마감가:
$27.91
열려 있는:
$28.13
하루 거래량:
1.85M
Relative Volume:
1.13
시가총액:
$4.72B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
22.34
EPS:
1.24
순현금흐름:
$315.22M
1주 성능:
-2.29%
1개월 성능:
-0.04%
6개월 성능:
+13.80%
1년 성능:
+16.58%
1일 변동 폭
$27.49
$28.18
1주일 범위
$27.11
$28.47
52주 변동 폭
$22.22
$32.88
Alkermes Plc Stock (ALKS) Company Profile
명칭
Alkermes Plc
전화
00-353-1-772-8000
주소
CONNAUGHT HOUSE, DUBLIN 4
ALKS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ALKS | 27.70 | 4.72B | 1.51B | 333.35M | 315.22M | 1.24 |
| ZTS | 176.71 | 79.55B | 9.15B | 2.43B | 2.31B | 4.92 |
| HLN | 9.55 | 43.18B | 14.26B | 1.55B | 0 | 0.3327 |
| TAK | 13.33 | 42.26B | 30.27B | 1.93B | 3.45B | 0.444 |
| TEVA | 17.08 | 19.35B | 16.77B | -959.00M | 1.37B | -2.00 |
| VTRS | 13.25 | 15.77B | 15.24B | -646.50M | 1.88B | 1.53 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-10-24 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-10-17 | 개시 | UBS | Neutral |
| 2022-11-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2022-08-16 | 개시 | Piper Sandler | Neutral |
| 2022-04-22 | 재개 | Goldman | Buy |
| 2022-04-20 | 개시 | Goldman | Buy |
| 2022-01-27 | 업그레이드 | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | 개시 | Citigroup | Neutral |
| 2021-10-07 | 업그레이드 | Jefferies | Hold → Buy |
| 2021-09-02 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-10-15 | 업그레이드 | Mizuho | Neutral → Buy |
| 2020-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2020-02-14 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | 재확인 | H.C. Wainwright | Neutral |
| 2020-02-14 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-02-06 | 개시 | Mizuho | Neutral |
| 2020-01-31 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | 업그레이드 | Goldman | Sell → Neutral |
| 2019-05-31 | 개시 | H.C. Wainwright | Neutral |
| 2019-05-01 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2018-12-19 | 다운그레이드 | Goldman | Neutral → Sell |
| 2018-12-14 | 개시 | Wolfe Research | Underperform |
| 2018-12-13 | 다운그레이드 | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | 개시 | Piper Jaffray | Neutral |
| 2018-08-07 | 개시 | Stifel | Hold |
| 2018-06-21 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | 개시 | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | 업그레이드 | Citigroup | Neutral → Buy |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
모두보기
Alkermes Plc 주식(ALKS)의 최신 뉴스
Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock? - Yahoo Finance
(ALKS) Trading Report - Stock Traders Daily
Alkermes (NASDAQ:ALKS) pulls back 6.0% this week, but still delivers shareholders respectable 5.8% CAGR over 5 years - Simply Wall St
Alkermes plc (NASDAQ:ALKS) Stock Position Decreased by Segall Bryant & Hamill LLC - MarketBeat
Substance Abuse Treatment Market Expected to Reach High Growth by 2031: Allergan PLC, Alkermes, Noramco. - openPR
Royce & Associates LP Grows Stock Holdings in Alkermes plc (NASDAQ:ALKS) - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Purchased by AMG National Trust Bank - MarketBeat
Brokerages Set Alkermes plc (NASDAQ:ALKS) PT at $35.42 - MarketBeat
Alkermes (NASDAQ:ALKS) Price Target Raised to $40.00 at Mizuho - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Principal Financial Group Inc. - MarketBeat
Alkermes to Participate in Two Upcoming Investor Conferences - Lelezard
Alkermes (ALKS) to Present at Major Healthcare Conferences: Stifel and Jefferies London | ALKS Stock News - StockTitan
Trend Tracker for (ALKS) - Stock Traders Daily
Alkermes plc (NASDAQ:ALKS) Shares Purchased by Robeco Institutional Asset Management B.V. - MarketBeat
Van ECK Associates Corp Purchases 29,998 Shares of Alkermes plc (NASDAQ:ALKS) - MarketBeat
Wellington Management Group LLP Adjusts Stake in Alkermes PLC - GuruFocus.com
Narcolepsy Insights from Alkermes Presented at Psych Congress and NEI Congress - Sleep Review
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences - Chicago Star Media
Alkermes EVP Craig Hopkinson sells $309,168 in stock - Investing.com
Alkermes EVP Craig Hopkinson sells $309,168 in stock By Investing.com - Investing.com Australia
Insider Sale at Alkermes PLC: EVP R&D, Chief Medical Officer Cra - GuruFocus.com
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 - MSN
Alkermes to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference - GuruFocus.com
Vanguard Group Inc's Recent Transaction in Alkermes PLC Shares - GuruFocus.com
Alkermes (NASDAQ:ALKS) Shares Gap UpHere's What Happened - MarketBeat
Alkermes raised to buy by Stifel on increased confidence for ALKS2680 (NASDAQ:ALKS) - Seeking Alpha
Alkermes PLC (ALKS) Shares Up 5.57% on Nov 5 - GuruFocus.com
Alkermes (NASDAQ:ALKS) Upgraded to Buy at Stifel Nicolaus - MarketBeat
A Glimpse Into The Expert Outlook On Alkermes Through 9 Analysts - Benzinga
Stifel raises Alkermes target to $36, upgrades to buy By Investing.com - Investing.com Australia
Stifel raises Alkermes target to $36, upgrades to buy - Investing.com India
Alkermes plc (NASDAQ:ALKS) Holdings Decreased by DekaBank Deutsche Girozentrale - MarketBeat
(ALKS) Proactive Strategies - Stock Traders Daily
Short Interest in Alkermes plc (NASDAQ:ALKS) Drops By 7.9% - MarketBeat
Alkermes plc (NASDAQ:ALKS) Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
Alkermes holds steady stock target with neutral rating amid royalty segment dip - Investing.com
Alkermes holds steady stock target with neutral rating amid royalty segment dip By Investing.com - Investing.com South Africa
Alkermes's SWOT analysis: innovative pipeline drives CNS stock's future - Investing.com
Alkermes Eyes Completion of Phase 2 Narcolepsy Studies in 2025 - Sleep Review
Goldman Sachs keeps Alkermes stock buy-rated ahead of milestone readouts, trims PT - Investing.com Canada
Piper Sandler cuts Alkermes stock target, keeps Overweight rating By Investing.com - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections - Investing.com Australia
Leerink maintains Alkermes stock rating with $28 target amid financial projections By Investing.com - Investing.com South Africa
Alkermes (NASDAQ:ALKS) PT Lowered to $30.00 - MarketBeat
Piper Sandler cuts Alkermes stock target, keeps Overweight rating - Investing.com
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down - MSN
Alkermes' Q3 Earnings & Revenues Fall Shy Of Estimates, Stock Down - Barchart
Alkermes' (ALKS) Overweight Rating Reiterated at Piper Sandler - MarketBeat
Alkermes plc (NASDAQ:ALKS) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Alkermes Plc reports solid Q3 growth, eyes future expansion - Investing.com
Alkermes Plc (ALKS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.01%
0.30%
자본화:
|
볼륨(24시간):